A
Argo Biopharma
Next-generation siRNA therapeutics for chronic diseases
About Argo Biopharma
Shanghai Bowang Pharmaceutical, operating as Argo Biopharma, is a clinical-stage biotechnology company founded in April 2021. The company was established by co-founders Dr. Dongxu Shu, the CEO, and Dr. Patrick Shao, the CSO, along with Shiwei Xia. Dr. Shu previously served as a senior scientist at Arrowhead Pharmaceuticals, focusing on extrahepatic delivery platforms, and holds a Ph.D. in chemistry from the University of Wisconsin-Madison. Dr. Shao has over two decades of experience in drug research, including roles at Mitotherapeutix and as Director of Medicinal Chemistry at Arrowhead Pharmaceuticals.
Argo Biopharma specializes in the discovery and development of next-generation small interfering RNA (siRNA) therapeutics. The firm's business model is centered on its proprietary RNAi platform technology, known as RADS (RNA molecules with superior Activity, Durability, and Safety). This platform is the foundation for a pipeline of drug candidates aimed at treating a wide range of indications, including cardiovascular and metabolic diseases, rare diseases, central nervous system (CNS) disorders, viral hepatitis, and complement-mediated diseases. The company's goal is to create transformative medicines for chronic disease management, with some drug candidates holding the potential for a single annual injection for certain indications.
The company operates in the global biopharmaceutical market and generates revenue through strategic partnerships, collaborations, and licensing agreements. A significant milestone was a strategic collaboration with Novartis in January 2024, involving substantial upfront payments and potential total value exceeding $4 billion. Since its inception, Argo has secured significant funding, including a nearly $5 million angel round in May 2021, a $63 million Series A round in March 2022, and a Series A+ round of over $40 million in November 2023. As of mid-2025, the company has multiple siRNA candidates in clinical development, with its first Investigational New Drug (IND) application approved in December 2022.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- China
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 54.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2023 | $41M | $413M | Trinity Innovation Fund · Tao Capital · Huagai Capital · SDIC Fund Management | ↗ |
Growth signals
Latest recorded traffic for Argo Biopharma is 1.7K monthly website visits, down 15% over the last three months. Argo Biopharma's team grew 580% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Argo Biopharma in its local ecosystem
The Argo Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Trinity Innovation Fund
Tao Capital
Huagai Capital
SDIC Fund Management
GSR United Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Argo Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Argo Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









